Sexuality and management of benign prostatic hyperplasia with alfuzosin 10mg once daily (Xatral OD 10mg), open, 24-week study.

Trial Profile

Sexuality and management of benign prostatic hyperplasia with alfuzosin 10mg once daily (Xatral OD 10mg), open, 24-week study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Acronyms SAMBA
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2008 Planned number of patients changed from 425 to 431 as reported by ClinicalTrials.gov.
    • 08 Apr 2008 Status changed form in progress to completed, as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top